FDA approves osteoarthritis drug from Nuvo Research
Canadian biotech firm Nuvo Research gained FDA approval for Pennsaid, a topical pain treatment for osteoarthritis of the knee. Nuvo and partner Covidien plan to introduce the product in the U.S. in the first half of 2010.
Reuters | 11/05
This story published in BIO SmartBrief on 11/06/2009
More from SmartBrief:
Transdel seeks partner to co-market pain drug candidate
Wednesday, October 14, 2009
Vasogen to merge with IntelliPharmaCeutics
Tuesday, August 18, 2009
Abbott to buy rights to Dutch biotech firm's pain drug
Friday, November 13, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|